Table 1 Studies of the effect of pneumococcal conjugates vaccines with meningitis outcomes.
| Â | Â | Quality Assessment | Directness | Â | Effect | |||||
|---|---|---|---|---|---|---|---|---|---|---|
No of studies | Doses | Design | Limitations | Consistency | Generalizability to Population of Interest | Generalizability to Intervention of Interest | Age range (months) | Events (control or pre-introduction) | Events (intervention or post-introduction) | Measure or Meta-estimate |
All-cause meningitis morbidity: High -quality measure of outcome-specific mortality | ||||||||||
1 [62] | 3 doses | RCT | High quality-None major | Not applicable | moderate-Africa | moderate-1 vaccine (PCV-9) | 1-30 | 8 | 7 | 0.87(0.32-2.41) |
All-cause mortality | ||||||||||
1 dose 3 doses (goal) | RCT | High quality-None major | high-evidence of dose-response effect | high-Africa | moderate-1 vaccine (PCV-9) | 1-30 | 389 242 | 330 229 | 0.90(0.80-1.01) | |
SP Meningitis, All-serotypes | ||||||||||
3 doses 3 doses (goal) | RCT | High quality-None major | high-consistent effect magnitude | high-Africa | moderate-1 vaccine (PCV-9) | 1-30 | 17 6 | 19 5 | 0.88(0.47-1.62) | |
SP Meningitis, Vaccine-serotypes | ||||||||||
3 doses 3 doses (goal) | RCT | High quality-None major | moderate-consistent direction of effect | high-Africa | moderate-1 vaccine (PCV-9) | 1-30 | 18 6 | 2 1 | 0.16(0.02-1.20) | |